Getting ahead of teasers here – maybe…one to keep an eye on but wondered what Thinkalator thoughts are…
The news on this is here: https://www.eurekalert.org/pub_releases/2021-02/uon-sup020121.php
Mipsagargin is a soluble thapsigargin prodrug and is apparently “stable in acidic pH, as found in the stomach, and therefore can be taken orally, so could be administered without the need for injections or hospital admission.”
Per NSPX’s latest 10-K: “(v) pursue licensing and/or partnering of mipsagargin, (vi) conduct a clinical study of mipsagargin in patients with advanced HCC, and (vii) explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.”
[Need to review 8-Ks]
Note that NSPX operations ceased in 2018 but it looks like they are starting them back up (see recent press release) based on recent capital injection.
Note also their beginning business was actually cancer therapies…
Don’t see any teasers but do see some conversions on yahoo finance…

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.